Tirzepatide has been one of the most legally contested drugs in telehealth in 2025–2026. The FDA's back-and-forth on shortage status, combined with federal court intervention, has created confusion for the millions of patients relying on compounded versions.
Here's a clear-eyed breakdown of where things stand and what it means for you.
The Shortage Designation: Why It Matters
Under federal law, compounding pharmacies can prepare copies of branded medications when those medications appear on the FDA's drug shortage list. This is the legal basis for compounded semaglutide and tirzepatide.
Tirzepatide (Mounjaro, Zepbound) was added to the shortage list as demand far exceeded Eli Lilly's manufacturing capacity. Millions of patients began accessing lower-cost compounded versions through telehealth companies, at a fraction of the branded price.
The FDA Removal Attempt
In late 2024, the FDA announced it was removing tirzepatide from the shortage list, stating that supply had improved sufficiently to meet demand. This would have ended legal compounding for tirzepatide.
Major compounding pharmacies and telehealth providers immediately challenged the decision, arguing: 1. The FDA's methodology for determining "shortage resolved" was flawed 2. Access to affordable medication would be eliminated for millions of patients 3. The transition timeline was insufficient for patients to switch to branded medication
The Court Reversal
Federal courts vacated the FDA's shortage resolution in early 2025, finding procedural issues with how the agency determined that the shortage had ended. This restored the legal basis for tirzepatide compounding.
As of early 2026, compounded tirzepatide from 503A and 503B pharmacies remains legal while litigation continues. The FDA has stated it intends to revisit the shortage determination. This is an ongoing situation.
What 503B Pharmacies Are and Why They Matter
Not all compounding pharmacies are equal. 503B pharmacies (also called "outsourcing facilities") are subject to: - FDA facility registration and inspection - Current Good Manufacturing Practice (cGMP) requirements - Batch testing and quality control documentation - Greater oversight than 503A (traditional compounding) pharmacies
Marrow uses exclusively FDA-registered 503B pharmacies. This is the highest available standard for compounded medications.
Tirzepatide vs. Semaglutide: The Clinical Case
From a pure efficacy standpoint, tirzepatide produces superior weight loss results:
| | Semaglutide (Wegovy) | Tirzepatide (Zepbound) | |---|---|---| | Peak dose weight loss (SURMOUNT-1/STEP 1) | ~15% at 68 weeks | ~22% at 72 weeks | | Mechanism | GLP-1 agonist | Dual GLP-1 + GIP agonist | | Cost (compounded) | ~$249/month | ~$299/month | | Dose titration | 16–20 weeks to max | 20–24 weeks to max |
For most patients, the additional cost of tirzepatide is justified by meaningfully better outcomes. The dual mechanism (GLP-1 + GIP) appears to work synergistically in ways that produce the extra 7% weight loss seen in trials.
Practical Guidance: What Should Patients Do?
If you're currently on compounded tirzepatide: Continue your protocol. The medication is legal, your prescriber is acting within current regulations. Stay informed through Marrow updates.
If you're deciding between semaglutide and tirzepatide: Both are viable options. Tirzepatide produces better average outcomes; semaglutide has a longer track record and broader data set.
If the regulatory situation changes: Marrow will communicate proactively. Options include transition to branded Zepbound (prior authorization pathway), switching to semaglutide, or waiting for legal resolution.
The bottom line: compounded tirzepatide is available today, legally, from properly regulated pharmacies. The situation requires monitoring, but it is not a reason to delay or discontinue treatment.
Frequently Asked Questions
Is compounded tirzepatide still legal in 2026?
Yes. Following legal challenges from compounding pharmacies and prescribers, courts vacated the FDA's resolution of the tirzepatide shortage, restoring the legal basis for compounding from 503A and 503B pharmacies. As of early 2026, compounded tirzepatide remains available through licensed telehealth providers using FDA-registered pharmacies. The situation is evolving — Marrow monitors regulatory updates and will notify patients of any changes.
How much does compounded tirzepatide cost?
Compounded tirzepatide at Marrow starts at $299/month. This includes the medication, injection supplies, physician oversight, and free shipping. Brand-name Zepbound costs $1,000–$1,200/month without insurance.
What's the difference between compounded and brand-name tirzepatide?
The active pharmaceutical ingredient is the same — tirzepatide. Compounded versions are prepared by FDA-registered 503B pharmacies rather than Eli Lilly. The regulatory pathway differs; compounded medications do not go through the same FDA approval process as brand-name drugs, but are prepared under strict manufacturing standards.
Will compounded tirzepatide be banned?
The legal situation has been volatile. The FDA initially removed tirzepatide from the shortage list, which would ban compounding. That decision was challenged in federal court and vacated. Ongoing litigation means the status could change. Patients on compounded tirzepatide should stay informed through their provider and have a contingency plan for accessing brand-name medication if needed.
Get our free Body Composition Guide
Protein protocols, workout structure, sleep optimization, and the supplement stack that actually works.
Get our free Body Composition Guide →
